Is Rezdiffra Covered by Insurance? What Patients Need to Know

Introduction

For patients living with MASH (metabolic dysfunction-associated steatohepatitis), the approval of Rezdiffra (resmetirom) marked a turning point. As the first FDA-approved treatment specifically designed for adults with noncirrhotic MASH with moderate to advanced liver fibrosis, Rezdiffra brought real hope to a population that had very few options for so long.

But hope doesn’t always come cheap — and that’s exactly why so many patients and caregivers are asking the same question: is Rezdiffra covered by insurance? For a newly approved speciality drug, navigating coverage can feel overwhelming, especially when the stakes involve a serious liver condition.

This article walks through everything patients need to know about Rezdiffra insurance coverage — from commercial plans and Medicare to cost-saving programs and how to fight a denial.

What Is Rezdiffra?

Rezdiffra is a prescription medication developed by Madrigal Pharmaceuticals. Its active ingredient, resmetirom, is a thyroid hormone receptor beta-selective agonist that targets the liver to reduce fat accumulation and fibrosis associated with MASH.

The FDA approved Rezdiffra in March 2024, making it the first and only approved pharmacological treatment for MASH — a condition that affects millions of Americans and can progress to cirrhosis, liver failure, or liver cancer if left untreated.

Cost Without Insurance

One of the most common concerns patients raise is the cost of Rezdiffra without insurance. Rezdiffra carries a steep list price — approximately $47,400 per year, or roughly $3,950 per month at its launch price. This figure alone makes understanding coverage absolutely critical for most patients. For those without any form of coverage, the cost of Rezdiffra without insurance is simply out of reach, which is why Madrigal has put support programs in place (covered further below).

Is Rezdiffra Covered by Insurance?

The short answer is: it depends on the plan. Rezdiffra insurance coverage varies based on the type of insurance a patient has, the specific plan’s formulary, and whether prior authorization is required. Here’s a breakdown by insurance type.

Commercial and Private Insurance

For patients with employer-sponsored or private insurance, Rezdiffra is increasingly being added to formularies as a specialty-tier drug. However, being on a formulary doesn’t mean access is automatic. Most commercial plans require prior authorization before they’ll cover Rezdiffra, and patients may face significant cost-sharing even with approval.

Coverage decisions often depend on whether the patient has a confirmed MASH diagnosis with documented fibrosis staging — typically Stage 2 or higher. Insurers may request liver biopsy results, imaging, and lab work to verify medical necessity.

Medicare Coverage

For Medicare beneficiaries, Rezdiffra falls under Part D (prescription drug coverage). Coverage and formulary placement can vary significantly from one Part D plan to another. Some plans may have placed Rezdiffra on a specialty tier with high cost-sharing, while others may not yet include it on their formulary at all.

Patients on Medicare should contact their specific Part D plan directly to confirm current formulary status. Those who find Rezdiffra isn’t covered may be able to request a formulary exception, especially with documented medical necessity from a specialist.

Medicaid

Medicaid coverage for Rezdiffra is among the most variable. Because Medicaid is administered at the state level, coverage policies differ widely. Some states may cover Rezdiffra for eligible patients, while others are still evaluating it or have restrictions in place. Patients on Medicaid are encouraged to work with their prescribing physician and a pharmacist or patient advocate who understands state-specific formulary policies.

Key Factors That Affect Coverage

Regardless of the insurance type, several factors commonly influence whether Rezdiffra gets covered:

Diagnosis codes: Accurate ICD-10 coding for MASH and liver fibrosis is essential. Incorrect or incomplete coding is a common reason for denials.

Fibrosis staging documentation: Most insurers want to see confirmation of moderate to advanced fibrosis (F2–F3), typically supported by liver biopsy or an approved non-invasive test.

Prescriber specialty: Some plans give more weight to prescriptions written by hepatologists or gastroenterologists rather than general practitioners.

Medical necessity documentation: Detailed clinical notes supporting the diagnosis and treatment rationale go a long way toward getting approval.

Prior Authorization: What to Expect

Prior authorization (PA) is a process insurers use to review whether a prescribed medication is medically necessary before they agree to cover it. For a specialty drug like Rezdiffra, prior authorization is almost always required.

Why Prior Authorization Is Commonly Required

Specialty medications carry high costs, so insurers use PA to confirm that the drug is being prescribed appropriately — meaning the patient genuinely has the condition the drug treats, and that simpler or cheaper alternatives have been considered.

Typical Documentation Needed

When a prescriber submits a PA request for Rezdiffra, they’ll typically need to include:

Recent lab results (liver enzymes, metabolic panels), liver imaging or elastography results, liver biopsy findings showing MASH with fibrosis staging of F2 or above, clinical notes confirming the diagnosis and treatment plan, and confirmation that the patient meets the FDA-approved indication.

How Long the Process Takes

PA decisions can take anywhere from a few days to several weeks, depending on the insurer. Some plans offer expedited or urgent review if the patient’s condition warrants it. Patients should follow up with both their provider’s office and their insurance company to keep the process moving.

What to Do If Prior Authorization Is Denied

A denial is not the end of the road. Patients have the right to appeal, and many denials are successfully overturned when additional documentation is provided. The prescriber’s office should be informed immediately so they can assist with the next steps.

How to Appeal a Denial

Receiving a denial letter can be discouraging, but it’s worth understanding that insurance denials — especially for newer specialty drugs — are common and often reversible.

Internal Appeal Process

The first step is to file an internal appeal directly with the insurance company. This typically involves submitting a written appeal along with additional clinical documentation. The patient’s physician plays a key role here, as a detailed letter of medical necessity from a specialist can significantly strengthen the case.

Appeals must usually be filed within a specific timeframe — often 30 to 180 days from the denial date — so patients should act promptly.

External Review Options

If an internal appeal is denied, patients have the right to request an independent external review. In this process, an independent organization reviews the insurer’s decision. External reviews are a legal right under the Affordable Care Act for most health plans, and insurers are bound by the outcome.

Tips for Working With Your Doctor

Patients should ask their hepatologist or gastroenterologist to write a personalized letter of medical necessity that directly addresses the insurer’s reason for denial. Including peer-reviewed clinical data about Rezdiffra’s efficacy and the risks of untreated MASH can make a compelling case.

Patient Assistance and Cost-Saving Options

Even if Rezdiffra insurance coverage comes through, out-of-pocket costs can still be significant. Fortunately, several programs exist to help reduce the financial burden.

Madrigal One Source

Madrigal Pharmaceuticals operates a patient support program called Madrigal One Source, designed to help patients access Rezdiffra. This program provides support with insurance navigation, prior authorization assistance, and connecting patients to financial assistance resources. Patients and providers can enroll through Madrigal’s official channels.

Co-Pay Assistance Cards

For patients with commercial insurance, Madrigal offers co-pay assistance that can significantly reduce what patients pay out of pocket for Rezdiffra cost with insurance. These cards are typically not available to patients on federal programs like Medicare or Medicaid due to legal restrictions.

Free Trial and Bridge Programs

Some patients may be eligible for a free trial supply of Rezdiffra while waiting for insurance approval — this is often called a “bridge program.” These short-term programs help ensure patients don’t go without treatment during the coverage review process.

Other Resources for Uninsured or Underinsured Patients

For those facing the full cost of Rezdiffra without insurance, additional resources include patient assistance programs (PAPs) offered directly by Madrigal, NeedyMeds (needymeds.org), RxAssist (rxassist.org), and the Patient Advocate Foundation. These organizations can help connect patients with free or reduced-cost medication options.

How to Check Your Coverage

Figuring out Rezdiffra insurance coverage doesn’t have to be a guessing game. Here’s a straightforward way to approach it.

Step-by-Step Guide to Calling Your Insurer

Patients should call the member services number on the back of their insurance card and ask specifically whether Rezdiffra (resmetirom) is covered under their plan. It helps to have the drug’s NDC (National Drug Code) on hand. Ask which tier it’s on, what the co-pay or coinsurance will be, and whether prior authorization is required.

Questions to Ask Your Insurance Company

Some helpful questions to ask include: Is Rezdiffra on my plan’s formulary? What are the prior authorization requirements? What documentation does my doctor need to submit? If it’s not covered, what is the process for requesting a formulary exception?

How Your Specialist Can Help

Hepatologists and gastroenterologists who treat MASH patients frequently are often very familiar with the coverage landscape for Rezdiffra. Many specialty practices have dedicated staff — sometimes called prior authorization coordinators — who handle this process routinely. Patients shouldn’t hesitate to lean on their specialist’s office for support.

Frequently Asked Questions

Conclusion

Navigating insurance coverage for a new specialty medication like Rezdiffra isn’t always simple, but it’s far from impossible. Whether someone has private insurance, Medicare, or Medicaid, there are pathways to getting Rezdiffra covered — and support programs available for those who need extra help covering the cost.

Patients and their families are encouraged to start the conversation with their hepatologist or gastroenterologist early. A specialist who understands MASH can be a powerful ally in the insurance process, helping gather the right documentation and advocating on the patient’s behalf.

For those looking for a direct starting point, reaching out to Madrigal One Source is a smart first step. Their team is specifically set up to guide patients through insurance hurdles and connect them to financial assistance when needed.

No one should have to go without a medication that could slow or reverse serious liver damage — and with the right support, most patients can find a way to access Rezdiffra.

Also Read: Apretude Cost With Insurance: Complete Guide to Coverage & Savings